AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States.
The last earnings update was 9 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AIM ImmunoTech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AIM ImmunoTech's earnings available for a low price, and how does
this compare to other companies in the same industry?
AIM ImmunoTech's earnings are expected to grow by 17.9% yearly, however this is not considered high growth (20% yearly).
AIM ImmunoTech's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AIM ImmunoTech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Thomas K. Equels, Esq. M.S., J.D. serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.) since February 25, 2016 and serves as its President since August 13, 2015. Mr. Equels has been an Executive Vice Chairman at AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.) since 2008 and served as its Secretary since January April 2009. He serves as Litigation Counsel of Hemispherx Biopharma Inc., in a number of complex cases over few years. He was owner of the Equels Law Firm. He served as the President and Managing Director of Equels Law Firm. He served as the Chief Financial Officer of Hemispherx Biopharma, Inc. since December 4, 2013 until February 19, 2015. He served as General Counsel of Hemispherx Biopharma, Inc. from January 1, 2010 to October 1, 2016. He served as Managing Director of Holtzman Equels P.A. For more than many years, he has represented national and state governments, banks, insurance companies, aviation companies, construction and development companies. Mr. Equels has extensive experience in international matters and served as counsel for the Republic of Panama, Chinese National Petroleum Corp. and worked extensively in Europe as well as in South America, Asia and Africa. He served as a Co-General Counsel of Hemispherx Biopharma, Inc from May 15, 2009 to January 1, 2010. He has been a Director at Hemispherx Biopharma, Inc. since November 28, 2008. He is a Member of the Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree in Management from Troy University.
Thomas's compensation has been consistent with company performance over the past year, both up more than 20%.
Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the AIM ImmunoTech management team is over 5 years, this suggests they are a seasoned and experienced team.
Executive Vice Chairman
CFO & Chief Accounting Officer
COO, Executive Director of Governmental Relations
Ann Marie Coverly
Director of Administration & Human Resources and Deputy Investor Relations Coordinator
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.